Miami, FL – November 20, 2019 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on AngioSoma, Inc. (OTC Pink: SOAN).
AngioSoma, Inc. operates as a clinical stage biotechnology company. The company’s lead drug candidates include Liprostin that completed Phase I and three Phase II clinical trials, and Prostaglandin E1 that completed Phase II clinical trials for the treatment of peripheral artery diseases. It also markets a line of nutraceutical supplements under the SomaCeuticals name.
Average daily volume for SOAN 2 million shares. Today’s news has caused the volume to increase to over 3.7 million shares in the morning hours of trading.
AngioSoma, Inc. Press Release:
Houston, TX, Nov. 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE –AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) today announced that holders of the Company’s 12% unsecured convertible notes in the principal amount of $469,000 maturing not later than June 30, 2020 (the “Notes”) elected to convert their Notes, resulting in $469,000 of the principal amount of the Notes being settled and reducing AngioSoma’s annual interest expense by approximately $56,000 through repayment of $469,000 of debt.
“The successful repayment of the majority of the Notes has strengthened our balance sheet and effectively left AngioSoma with substantially less long-term debt payable,” said Alex Blankenship, CEO of AngioSoma. “The additional funding received from the partial conversion of the Notes further strengthens our financial position as we continue to execute the roll-out of our Muscles4U workout enhancement products later this year.”
ABOUT ANGIOSOMA, INC.
AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals™. SomaCeuticals’s experienced team of industry first movers and enterprising visionaries has acquired a diversified supply of supplements, strong clinical, scientific and operating capabilities and leading product research and development infrastructure in order to create trusted products and brands in an expanding global market.
Learn more at www.muscles4U.com and htttps://muscles4u.blogstop.com.
Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook
NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
(832) 781- 8521
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.